A New Era of Regulatory Transparency: What Life Sciences Companies Should Know About the SEC-FDA’s New MOU
The SEC-FDA Memorandum of Understanding (MOU) signals more than interagency coordination. It reinforces the need for life sciences companies to align regulatory facts, investor communications, and disclosure controls with greater discipline. Here is why the agreement matters and how companies can respond proactively. On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and…

